SEC Comment Letter 0000000000-23-013970 to Gain Therapeutics, Inc. (GANX) (CIK 0001819411) (GANX)
Gain Therapeutics, Inc. (GANX) (CIK 0001819411)
Date: Dec. 21, 2023 · CIK: 0001819411 · Accession: 0000000000-23-013970
AI Filing Summary & Sentiment
File numbers found in text: 333-276145
Letter
United States securities and exchange commission logo December 21, 2023 Matthias Alder Chief Executive Officer Gain Therapeutics, Inc. 4800 Montgomery Lane, Suite 220 Bethesda, Maryland 20814 Re:Gain Therapeutics, Inc. Registration Statement on Form S-1 Filed December 19, 2023 File No. 333-276145 Dear Matthias Alder: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steven M. Skolnick, Esq.
Show Raw Text
United States securities and exchange commission logo
December 21, 2023
Matthias Alder
Chief Executive Officer
Gain Therapeutics, Inc.
4800 Montgomery Lane, Suite 220
Bethesda, Maryland 20814
Re:Gain Therapeutics, Inc.
Registration Statement on Form S-1
Filed December 19, 2023
File No. 333-276145
Dear Matthias Alder:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Steven M. Skolnick, Esq.